ARNI initiation after acute decompensated heart failure reduced HF rehospitalization/all-cause mortality by 29% and worsening renal function by 20%, but increased symptomatic hypotension risk by 33%.
Does the initiation of ARNI reduce heart failure rehospitalization or all-cause mortality compared to ACEIs/ARBs in patients with stabilized acute decompensated heart failure?
Initiation of ARNI after stabilization of acute decompensated heart failure significantly reduces HF rehospitalization and all-cause mortality compared to ACEIs/ARBs, though it increases the risk of symptomatic hypotension.
Absolute Event Rate: 0% vs 0%
Abstract Purpose Angiotensin receptor-neprilysin inhibitors (ARNI) are well-established for chronic heart failure (HF) with reduced ejection fraction. However, their efficacy and safety when initiated in acute decompensation (ADHF) remain less well characterized. This meta-analysis evaluates the efficacy and safety of ARNI compared to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for ADHF. Methods A meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, Scopus, WOS, Embase, and CENTRAL till November 2024. Risk ratios (RR) were applied for dichotomous outcomes and standardized mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). Results Three RCTs with 1,741 patients were included. Use of ARNI after stabilization of ADHF resulted in a significant reduction of HF rehospitalization/all-cause mortality (RR: 0.71; 95% CI: 0.57 to 0.88; p 0.01), HF rehospitalization (RR: 0.73; 95% CI: 0.57 to 0.93; p = 0.01), worsening renal function (RR: 0.80; 95% CI: 0.64 to 1.00; p = 0.048), and NT-proBNP at 4 weeks (SMD: -0.24; 95% CI: -0.34 to -0.14; p 0.0001) or 8 weeks (SMD: -0.21; 95% CI: -0.31 to -0.10; p = 0.0001). However, ARNI was associated with a higher risk of symptomatic hypotension (RR: 1.33; 95% CI: 1.04 to 1.71; p = 0.024). Conclusion Pooled data demonstrate that the initiation of ARNI post-ADHF can be effective compared with ACEIs/ARBs for both cardiovascular and renal benefits at the expense of increased risk for symptomatic hypotension.
Hunjul et al. (Sat,) reported a other. ARNI initiation after acute decompensated heart failure reduced HF rehospitalization/all-cause mortality by 29% and worsening renal function by 20%, but increased symptomatic hypotension risk by 33%.